Clinicopathologic Profile and Treatment Outcomes of Children With Diffuse Large B-cell Lymphomas: Experience From a Tertiary Cancer Center in India. Issue 3 (3rd April 2022)

• Record Type: Journal Article
• Authors: Mande, Radnyi; Roy Moulik, Nirmalya; Shet, Tanuja; Narula, Gaurav; Prasad, Maya; Dhamne, Chetan; Bhat, Vasudeva; Cheriyalinkal Parambil, Badira; Shah, Sneha; Shridhar, Epari; Gujral, Sumeet; Banavali, Shripad
• Is Part Of: Journal of pediatric hematology/oncology. Volume 44:Issue 3(2022)
• Page Start: e760
• Page End: e764
• Publication Date: 2022-04-03
• Subjects: diffuse large B-Cell lymphoma -- high-dose methotrexate -- MCP-842 protocol; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; 618.9215
• DOI: 10.1097/MPH.0000000000002378
• Languages: English
• ISSNs: 1077-4114

Abstract

Abstract : Clinicopathologic profile and outcome of 15 children (15 years or above) with diffuse large B-cell lymphoma treated with MCP-842 protocol are reported. Eleven of 15 presented with advanced (stage-III/IV) disease. Post-2 cycles of chemotherapy, complete metabolic and morphologic response was documented in 10 (66%) and rest 5 (33%) with partial response achieved complete metabolic remission by end of treatment. At a median follow-up of 44 months (range: 16 to 79 mo), the 3-year event-free survival and overall-survival were 77.1%±11.7% and 85.7%±9.4%, respectively. Though majority of our patients had advanced disease, outcome on MCP-842 protocol was satisfactory.